CD8A and chronic myelogenous leukemia, BCR-ABL1 positive: These distinct features suggest that key mechanistic differences underlie the genesis and maintenance of dominant CD8+ TCR-Vβ+ expansions in T-LGLL and dasatinib-treated CML patients.